Access the full text.
Sign up today, get DeepDyve free for 14 days.
(1979)
ment of mice: central receptor subsensitiviry or supersensitivity?
A. Bonnet, Y. Loria, M. Saint-Hilaire, F. Lhermitte, Y. Agid (1987)
Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions?Neurology, 37
(1986)
selective D-1 and D-2 dopamine receptor agonists
Shibuya Shibuya (1979)
Dopamine‐sensitive adenylate cyclase activity in the striatum in Parkinson's diseaseJ Neural Transm, 44
J. Nutt, W. Woodward, J. Hammerstad, J. Carter, John Anderson (1984)
The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.The New England journal of medicine, 310 8
D. Chicot, R. Wright, B. Brotman, A. Prince (1975)
HEPANOSTICON IN SCREENING FOR HBsAgThe Lancet, 305
MD Jong, MD Meerwaldt, PhDt Schmitz, D. Meerwaldt (1987)
Factors that influence the occurrence of response variations in Parkinson's diseaseAnnals of Neurology, 22
Bailey Bailey, Jackson Jackson, Bracs Bracs (1979)
Long‐term L‐dopa pretreatment of mice: central receptor subsensitivity or supersensitivityPsychopharmacology, 66
O. Hornykiewicz (1974)
The mechanisms of action of L-dopa in Parkinson's disease.Life sciences, 15 7
Subhash Sharma, D. Kleinbaum, L. Kupper (1978)
Applied Regression Analysis and Other Multivariate Methods
J. Juncos, M. Mouradian, G. Fabbrini, C. Serrati, T. Chase (1987)
Levodopa methyl ester treatment of Parkinson's diseaseNeurology, 37
S. Diamond, Charles Marchkham, M. Hoehn, F. Mcdowell, M. Muenter (1987)
Multi‐center study of Parkinson mortality with early versus later dopa treatmentAnnals of Neurology, 22
E. Melamed, F. Hefti, R. Wurtman (1980)
Nonaminergic striatal neurons convert exogenous l‐dopa to dopamine in parkinsonismAnnals of Neurology, 8
J. Ajuriaguerra, G. Gauthier (1971)
Monoamines noyaux gris centraux et syndorme de Parkinson
M. Mouradian, J. Juncos, C. Serrati, G. Fabbrini, S. Palmeri, T. Chase (1987)
Exercise and the Antiparkinsonian Response to LevodopaClinical Neuropharmacology, 10
Muenter, Tyce Gm (1971)
L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.Mayo Clinic proceedings, 46 4
S. Fahn (1974)
“On‐off” phenomenon with levodopa therapy in parkinsonismNeurology, 24
R. Sweet, F. Mcdowell (1974)
Plasma dopa concentrations and the “on‐off” effect after chronic treatment of Parkinson's diseaseNeurology, 24
C. Négre (1986)
[Treatment of Parkinson's disease].Soins; la revue de reference infirmiere, 474
MD Direnfeld, ”. Spero, MD Marotta, MD Seeman (1978)
The L‐dopa on‐off effect in parkinson disease: Treatment by transient drug withdrawal and dopamine receptor resensitizationAnnals of Neurology, 4
A. Barbeau (1970)
Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.Neurology, 20 4
H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, F. Seitelberger (1973)
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.Journal of the neurological sciences, 20 4
MD Fabbrini, MD Juncos, MD Mouradian, MD Serrati, M. Chase (1987)
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's diseaseAnnals of Neurology, 21
Compensatory biochemical changes at the striatal dopamine synapse in Parkinson ’ s disease - limitations of L - dopa therapy
T. Chase, E. Holden, J. Brody (1973)
Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis.Archives of neurology, 29 5
C. Markham, S. Diamond (1981)
Evidence to support early levodopa therapy in Parkinson diseaseNeurology, 31
S. Pullman, R. Watts, J. Juncos, T. Chase, J. Sanes (1988)
Dopaminergic effects on simple and choice reaction time performance in Parkinson's diseaseNeurology, 38
J. Nutt, W. Woodward (1986)
Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patientsNeurology, 36
Juncos Juncos, Fabbrini Fabbrini, Mouradian Mouradian (1987)
Controlled release levodopa treatment of motor fluctuations in Parkinson's diseaseJ Neurol NeJrosurg Psychiatry, 50
K. Leenders, A. Palmer, N. Quinn, J. Clark, G. Firnau, E. Garnett, C. Nahmias, T. Jones, C. Marsden (1986)
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.Journal of Neurology, Neurosurgery & Psychiatry, 49
M. DeLong, M. Crutcher, A. Georgopoulos (1983)
Relations between movement and single cell discharge in the substantia nigra of the behaving monkey, 3
(1986)
Pharmacodynamic aspects of drug action
H. Rosengarten, J. Schweitzer, A. Friedhoff (1986)
Selective dopamine D2 receptor reduction enhances a D1-mediated oral dyskinesia in rats.Life sciences, 39 1
E. Levin, R. Bowman (1986)
Behavioral Effects of Chronic Exposure to Low Concentrations of Halothane during Development in RatsAnesthesia & Analgesia, 65
F. Javoy, J. Glowinski (1971)
DYNAMIC CHARACTERISTICS OF THE ‘FUNCTIONAL COMPARTMENT’ OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUMJournal of Neurochemistry, 18
W. Weiner, W. Koller, S. Perlik, P. Nausieda, H. Klawans (1980)
Drug holiday and management of Parkinson diseaseNeurology, 30
Costall Costall, Domeney Domeney, Naylor Naylor (1983)
A comparison of the behavioural consequences of chronic stimulation of dopamine receptors in the nucleus accumbens of rat brain effected by a continuous infusion or by single daily injectionsNaunyn Schmiedeberg's Arch Pharmacol, 324
Rinne Rinne, Lonnberg Lonnberg, Koskinen Koskinen (1981)
Dopamine receptors in the parkinsonian brainJ Neural Transm, 51
MD Obeso, MD Luquin, MD Lage, Disease Obeso (1986)
Intravenous lisuride corrects oscillations of motor performance in Parkinson's diseaseAnnals of Neurology, 19
C. Marsden, J. Parkes (1977)
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASEThe Lancet, 309
Muenter, Sharpless Ns, Tyce Gm, Darley Fl (1977)
Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.Mayo Clinic proceedings, 52 3
A. Barbeau (1970)
Rationale for the use of L‐dopa in the torsion dystoniasNeurology, 20
A. Groppetti, C. Flauto, E. Parati, A. Vescovi, L. Rusconi, M. Parenti (1986)
Dopamine receptor changes in response to prolonged treatment with L-dopa.Journal of neural transmission. Supplementum, 22
C. Pimoule, H. Schoemaker, Gavin Reynolds, S. Langer (1985)
[3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease.European journal of pharmacology, 114 2
B. Djahanguiri, S. Hemmati, D. Sadeghi, A. Firouzabadi (1967)
The prevention of acute gastric ulcer in the rat by alpha-methyldopa.Medicina et pharmacologia experimentalis. International journal of experimental medicine, 17 5
A. Barbeau (1969)
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.Canadian Medical Association journal, 101 13
G. Fabbrini, J. Juncos, M. Mouradian, C. Serrati, T. Chase (1987)
3–0‐methyldopa and motor fluctuations in Parkinson's diseaseNeurology, 37
A. Lees, G. Stern (1981)
Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 44
R. Raisman, R. Cash, M. Ruberg, F. Javoy‐Agid, Y. Agid (1985)
Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects.European journal of pharmacology, 113 3
C. Pycock, D. Dawbarn, C. O'shaughnessy (1982)
Behavioural and biochemical changes following chronic administration of L-dopa to rats.European journal of pharmacology, 79 3-4
G. Cotzias, P. Papavasiliou, R. Gellene (1969)
Modification of Parkinsonism--chronic treatment with L-dopa.The New England journal of medicine, 280 7
G. Cotzias, Van Mh, Schiffer Lm (1967)
Aromatic amino acids and modification of parkinsonism.The New England journal of medicine, 276 7
(1978)
Pharmacodynamics : mechanisms of drug action and the relationship between drug concentration and effect
J. Wagner, P. Vitali, M. Palfreyman, M. Zraika, Stéphane Huot (1982)
Simultaneous Determination of 3,4‐Dihydroxyphenylalanine, 5‐Hydroxytryptophan, Dopamine, 4‐Hydroxy‐3‐Methoxyphenylalanine, Norepinephrine, 3,4‐Dihydroxyphenylacetic Acid, Homovanillic Acid, Serotonin, and 5‐Hydroxyindoleacetic Acid in Rat Cerebrospinal Fluid and Brain by High‐Performance Liquid ChroJournal of Neurochemistry, 38
C. Markham, S. Diamond (1986)
Long‐term follow‐up of early dopa treatment in Parkinson's diseaseAnnals of Neurology, 19
H. Doller, J. Connor (1980)
Changes in Neostriatal Dopamine Concentrations in Response to Levodopa InfusionsJournal of Neurochemistry, 34
MD Mouradian, MD Juncos, MD Fabbrini, M. Chase (1987)
Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studiesAnnals of Neurology, 22
Allen Braun, Thomas Chase (1986)
Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors.European journal of pharmacology, 131 2-3
K. Wilner, I. Butler, W. Seifert, Y. Clement-Cormier (1980)
Biochemical alterations of dopamine receptor responses following chronic L-dopa therapy.Biochemical pharmacology, 29 5
R. Lesser, S. Fahn, S. Snider, L. Cote, W. Isgreen, R. Barrett (1979)
Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapyNeurology, 29
B. Bunney, J. Walters, R. Roth, G. Aghajanian (1973)
Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity.The Journal of pharmacology and experimental therapeutics, 185 3
P. Nathan (1975)
RECENT ADVANCES ON PAIN: PATHOPHYSIOLOGY AND CLINICAL ASPECTSJournal of Neurology, Neurosurgery & Psychiatry, 38
Belinda Bokobza, M. Ruberg, B. Scatton, F. Javoy‐Agid, Y. Agid (1984)
[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.European journal of pharmacology, 99 2-3
Braun Braun, Chase Chase (1986)
Behavioral effects of chronic exposure to selective D‐1 and D‐2 dopamine receptor agonistsNeurosci Abstr, 12
S. Ogasahara, Y. Nishikawa, Mitsuo Takahashi, K. Wada, Yusaku Nakamura, S. Yorifuji, S. Tarui (1984)
Dopamine metabolism in the central nervous system after discontinuation of l-dopa therapy in patients with Parkinson diseaseJournal of the Neurological Sciences, 66
Besson Besson, Cheramy Cheramy, Feltz Feltz, Glowinski Glowinski (1969)
Release of newly synthesized dopamine from dopamine‐containing terminals in the striatum of the ratProc Nad Acad Sci USA, 62
H. Klawans, C. Goetz, P. Nausieda, W. Weiner (1977)
Levodopa‐Induced dopamine receptor hypersensitivityAnnals of Neurology, 2
Jl Juncos, Giovanni Fabbrini, M. Mouradian, C. Serrati, A. Kask, Thomas Chase (1987)
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 50
K. Shaw, A. Lees, G. Stern (1980)
The impact of treatment with levodopa on Parkinson's disease.The Quarterly journal of medicine, 49 195
Long-term L-dopa pretreat-1977
C. Marsden, J. Parkes (1976)
"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPYThe Lancet, 307
J. Nutt, W. Woodward, J. Carter (1986)
Clinical and biochemical studies with controlled‐release levodopa/carbidopaNeurology, 36
J. Juncos, G. Fabbrini, M. Mouradian, C. Serrati, T. Chase (1987)
Dietary influences on the antiparkinsonian response to levodopa.Archives of neurology, 44 10
Tyrone Lee, P. Seeman, A. Rajput, I. Farley, O. Hornykiewicz (1978)
Receptor basis for dopaminergic supersensitivity in Parkinson's diseaseNature, 273
MD Fabbrini, MD Mouradian, MD Juncos, MD Schlegel, PhD Mohr, M. Chase (1988)
Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part IAnnals of Neurology, 24
Hoehn Hoehn, Yahr Yahr (1967)
Parkinsonism: onset, progression and mortalityNeurology, 17
M. Besson, A. Chéramy, P. Feltz, J. Glowinski (1969)
Release of newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat.Proceedings of the National Academy of Sciences of the United States of America, 62 3
A. Barbeau (1974)
The clinical physiology of side effects in long-term L-DOPA therapy.Advances in neurology, 5
(1987)
Long-term duodenal infusion of levodopa for on-off phenomenon in parkin-sonism: continued good clinical response associated with gradually declining levodopa intake
The contribution of central pharmacodynamic mechanisms to the pathogenesis of motor fluctuations in advanced Parkinson's disease was studied in 29 patients by evaluating their acute response to intravenously injected. levodopa. While the threshold dose for an antiparkinsonian effect did not change, that for induction of dyskinesia showed a progressive reduction in 4 groups: (1) levodopa‐naive patients, (2) those with a stable response to oral administration, and (3) those with wearing‐off or (4) on‐off fluctuations. Concomitantly, the therapeutic window for levodopa narrowed and the levodopa dose—antiparkinsonian response slope increased. The antiparkinsonian threshold dose correlated best with duration of symptoms; the dyskinesia threshold dose, therapeutic window, and dose‐response slope related most closely with the duration of levodopa treatment. The differing dose‐response profiles for the antiparkinosonian and dyskinetic effects suggest involvement of Septemberarate pharmacological mechanisms. The present results, taken together with previous observations that the wearing‐off phenomenon responds promptly to plasma levodopa stabilization while on‐off fluctuations tend to diminish over several days, suggest that postsynaptic modifications, presumably at the receptor level, serve as the major determinant for the increasing difficulty with optimal dose adjustment and motor fluctuations, especially of the on‐off type, which complicate levodopa therapy of patients with advance Parkinson's disease.
Annals of Neurology – Wiley
Published: Sep 1, 1988
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.